Elite Pharmaceuticals (OTCQB:ELTP) has received FDA approval for a generic version of Shire’s Adderall XR, an extended-release mixed salt of a single entity Amphetamine product with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg tablets.
The product is a central nervous system stimulant and is indicated for the treatment of Attention Deficit Hyperactivity Disorder.
According to IQVIA, the branded product and its equivalents had total U.S. sales of $1.3B for year ended October 2019.
Generic Adderall XR is jointly owned and the second product of Elite and SunGen Pharma collaboration.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.